Ethylene oxide (EO) sterilization is widely used for single-use sterile syringes, but residual EO and its reaction by-products can pose serious toxicological risks to patients if not properly controlled. Ethylene oxide residue testing, typically performed by headspace gas chromatography, verifies that residuals in the barrel, plunger stopper, and needle components remain within the limits specified by ISO 10993-7, GB/T 16886.7, and GB/T 14233.1 before products are released to market. This article explains the applicable standards, residue limits, sample preparation, analytical procedures, and common questions involved in single-use syringe EO residue testing.
Technical Overview
Ethylene oxide (EO, also written as EtO) is a low-temperature, broad-spectrum alkylating sterilant that is particularly suitable for heat- and moisture-sensitive medical devices. Single-use syringes, which combine polypropylene barrels, rubber piston stoppers, silicone lubricant, stainless steel needles, and plastic protective caps, are commonly sterilized with EO because the cycle temperature is gentle on these polymer components.
However, EO is toxic, irritating, sensitizing, and classified as a Group 1 carcinogen by IARC. Because polymer materials, especially rubber components, absorb EO during sterilization and release it slowly afterward, measurable residues can remain in the finished device. In addition, EO reacts with water and chloride-containing materials to form degradation products such as ethylene chlorohydrin (ECH, 2-chloroethanol) and ethylene glycol (EG), which also carry toxicological risk. Residual EO entering the bloodstream through a injected drug may cause hemolysis, local irritation, hypersensitivity, or systemic toxicity.
The level of residue depends on multiple factors, including material composition, sterilization cycle parameters (temperature, EO concentration, exposure time, relative humidity), load configuration, aeration time and temperature, packaging permeability, and post-sterilization storage duration. EO residue testing is therefore an essential quality control and safety step, and it is also a required element of sterilization process validation under ISO 11135 and of product registration dossiers in most major markets.
Testing Samples
Finished Sterile Single-Use Syringes
The primary test article is the finished, EO-sterilized single-use syringe in its final primary packaging, sampled after the completion of the aeration phase. Typical test samples include luer-lock and luer-slip syringes ranging from 1 mL to 60 mL, with or without mounted needles. Sampling should be representative of the sterilization load, and worst-case load positions should be considered during validation studies.
Syringe Components and Materials
Component-level testing is frequently performed during product development, aeration cycle design, and sterilization validation. Common test articles include polypropylene barrels and plungers, bromobutyl or isoprene rubber pistons, needle hubs, protective caps, and the breathable packaging materials such as Tyvek pouches. Rubber components usually show the highest EO absorption and are often the critical material driving the aeration time.
Related EO-Sterilized Devices
The same analytical methodology applies to other EO-sterilized single-use devices, including infusion sets, scalp vein sets, hypodermic needles, intravenous cannulae, and catheters, which are frequently evaluated alongside syringes during comprehensive type testing programs.
Testing Items
The core testing items for EO-sterilized single-use syringes include:
- Ethylene oxide (EO) residue content, reported in micrograms per gram (µg/g) of sample and/or milligrams (mg) per device.
- Ethylene chlorohydrin (ECH, 2-chloroethanol) residue, which is significant when chloride-containing materials or saline contact pathways are present.
- Ethylene glycol (EG) residue, where the applicable product standard or risk assessment requires it.
Acceptance criteria are primarily governed by ISO 10993-7 and its Chinese adoption GB/T 16886.7, which set tolerable limits according to patient contact duration. For limited-exposure devices with patient contact of 24 hours or less, the category that applies to most single-use syringes, the limits are 4 mg for EO and 9 mg for ECH per device. For prolonged-contact devices (24 hours to 30 days), the limits are tightened to 2 mg for EO and 5 mg for ECH, and permanent-contact devices are subject to even stricter limits. In China, many product standards for injection and infusion devices additionally specify an EO residue limit of no more than 10 µg/g per device when tested according to GB/T 14233.1, and manufacturers must confirm the exact criteria cited in their applicable product standard or registration specification.
Testing Methods
Sample Preparation and Extraction
Two extraction approaches are recognized. The simulated-use extraction fills the syringe with a defined volume of water, holds it under specified temperature and time conditions to mimic clinical use, and analyzes the resulting extract. The exhaustive extraction performs repeated successive extractions of cut sample pieces until the remaining residue is negligible, which is used to determine total residual content. For routine release testing of syringes, the simulated-use approach is generally preferred because it reflects the dose actually delivered to the patient.
Headspace Gas Chromatography (HS-GC-FID)
The reference method in GB/T 14233.1 is headspace gas chromatography with flame ionization detection. In a typical procedure, a representative portion of the syringe is cut into small pieces, accurately weighed, and sealed in a headspace vial with a defined volume of water. The vial is equilibrated in the headspace autosampler at an elevated temperature so that residual EO partitions into the headspace, after which an aliquot is injected into a capillary GC column equipped with an FID detector. Quantification is performed by external standard calibration using certified EO and ECH reference solutions. ECH can be analyzed by the same instrument platform using an appropriate headspace or liquid injection technique, and EG is determined where required using a validated chromatographic method.
Method Validation and Calculation
The analytical method must be validated for linearity (typically a calibration correlation coefficient of at least 0.99), accuracy and recovery, precision, and detection limits at the sub-microgram-per-gram level. The residue content is calculated from the calibrated concentration in the extraction medium, the extraction volume, and the sample mass, giving a result in µg/g that can be converted to mg per device using the measured device mass. Results from all tested units are reported, and each unit or the statistical evaluation must comply with the applicable limit. Any out-of-specification result triggers an investigation into sterilization records, aeration parameters, and sampling timing.
Applications
EO residue testing for single-use syringes supports the following activities:
- Routine quality control and batch release following EO sterilization and aeration.
- Initial performance qualification and annual requalification of EO sterilization processes under ISO 11135, including worst-case load mapping.
- Development of aeration cycles and degassing kinetic studies that establish residue-versus-time decline curves for setting release times.
- Product registration and market submissions, including NMPA type testing in China, EU MDR technical documentation, and FDA regulatory filings.
- Evaluation of material changes (for example, a new rubber piston formulation) and packaging changes (for example, breathable versus non-breathable pouches) that may affect EO absorption and dissipation.
- Investigation of out-of-specification batches, customer complaints, and third-party or arbitration testing.
FAQ
Why do single-use syringes need EO residue testing?
Because the polymers and rubbers in syringes absorb EO during sterilization and release it gradually. If residues are not confirmed to be within safe limits, residual EO and its by-products can migrate into the injected medication and expose the patient to a toxic, sensitizing, and carcinogenic compound. Testing is a regulatory expectation and a prerequisite for batch release and product registration.
What standards govern EO residue testing of syringes?
ISO 10993-7 and GB/T 16886.7 define the allowable residue limits, GB/T 14233.1 provides the standard gas chromatographic test methods, GB 15810 specifies requirements for single-use sterile syringes in China, and ISO 11135 governs the EO sterilization process itself, including the requirement for residual studies during validation.
How many samples should be tested and when should they be sampled?
For batch release, typically no fewer than three devices per sterilization batch are tested, while validation studies use larger sample sets covering worst-case load positions. Samples must be taken after the aeration phase is complete and analyzed promptly, because EO continues to dissipate over time. The elapsed time between sterilization and testing should always be recorded and controlled.
Why do EO residue results vary between batches?
Variation can arise from differences in load density and configuration, sterilization cycle humidity and temperature, aeration time and airflow, rubber component lots, packaging permeability, and the storage interval before testing. Consistent control of these parameters and periodic trend analysis keep results stable and well below limits.
What is a typical turnaround time for testing?
For a routine headspace GC analysis with established methods, results are generally available within three to seven working days of sample receipt. Validation of a new method, a new matrix, or a full ISO 11135 residual study requires additional time for protocol design and multiple sampling intervals.
Can EO and ECH be determined from the same sample?
In many cases, EO and ECH can be analyzed from a shared extraction solution using separate calibrated chromatographic sequences, which improves efficiency and consistency. However, EG and other by-products may require dedicated methods, so the test plan should be defined based on the applicable product standard and the device risk assessment.